ProtoKinetix

ProtoKinetix (PKTX) is a leading research and development company in the field of cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunities, shaping the future of ophthalmology, dermatology, transplant support, and biomanufacturing. This anti-aging glycopeptide is based on molecules found in nature and utilized by a world-class research team to help more cells survive longer and has the potential to forever change healthcare. With AAGP, health therapies will become more effective, more affordable, and more accessible. We will be closer to treating diseases such as Type 1 diabetes, macular degeneration, heart disease, and stroke. More lives will be improved, and more people will receive the treatments they deserve. ProtoKinetix leverages molecules found in nature, possessing the power to transform the future of life and healthcare. Established in 2002, ProtoKinetix patented the anti-aging glycopeptide (AAGP), a naturally occurring molecule that regenerates cells for animals surviving in Arctic temperatures. AAGP has undergone a series of tests in laboratories across Europe and North America, conducted by some of the best researchers in the world. Supported by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable, and effective in protecting and regenerating cells. This molecule could be key to improving treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease, and more.